EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Formulation and Scale-up of Delamanid Nanoparticles via Emulsification for Oral Tuberculosis Treatment

Nicholas J Caggiano iD, Madeleine S Armstrong iD, Joanna S Georgiou, Aditya Rawal iD, Brian K Wilson, Claire E White iD, Rodney D Priestley iD, Robert K Prud'homme iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Nicholas J Caggiano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States. Hauptthemen laut MEDLINE: Tuberculosis, Oral, Nanoparticles. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delamanid (DLM) is a hydrophobic small molecule therapeutic used to treat drug-resistant tuberculosis (DR-TB). Due to its hydrophobicity and resulting poor aqueous solubility, formulation strategies such as amorphous solid dispersions (ASDs) have been investigated to enhance its aqueous dissolution kinetics and thereby improve oral bioavailability. However, ASD formulations are susceptible to temperature- and humidity-induced phase separation and recrystallization under harsh storage conditions typically encountered in areas with high tuberculosis incidence. Nanoencapsulation represents an alternative formulation strategy to increase aqueous dissolution kinetics while remaining stable at elevated temperature and humidity. The stabilizer layer coating the nanoparticle drug core limits the formation of large drug domains by diffusion during storage, representing an advantage over ASDs. Initial attempts to form DLM-loaded nanoparticles via precipitation-driven self-assembly were unsuccessful, as the trifluoromethyl and nitro functional groups present on DLM were thought to interfere with surface stabilizer attachment. Therefore, in this work, we investigated the nanoencapsulation of DLM via emulsification, avoiding the formation of a solid drug core and instead keeping DLM dissolved in a dichloromethane dispersed phase during nanoparticle formation. Initial emulsion formulation screening by probe-tip ultrasonication revealed that a 1:1 mass ratio of lecithin and HPMC stabilizers formed 250 nm size-stable emulsion droplets with 40% DLM loading. Scale-up studies were performed to produce nearly identical droplet size distribution at larger scale using high-pressure homogenization, a continuous and industrially scalable technique. The resulting emulsions were spray-dried to form a dried powder, and in vitro dissolution studies showed dramatically enhanced dissolution kinetics compared to both as-received crystalline DLM and micronized crystalline DLM, owing to the increased specific surface area and partially amorphous character of the DLM-loaded nanoparticles. Solid-state NMR and dissolution studies showed good physical stability of the emulsion powders during accelerated stability testing (50 °C/75% RH, open vial).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, OralNanoparticlesHumansEmulsionsSolubilityExcipientsWaterParticle SizeNitroimidazolesOxazoles

Stichwörter der Autor:innen

emulsionencapsulationnanoparticleoral deliverytuberculosis

Substanzen

EmulsionsExcipientsWaterOPC-67683NitroimidazolesOxazoles

Autor:innen und Institutionen

  • Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States.
  • Mark Wainwright Analytical Centre, University of New South Wales, Sydney, NSW 2032, Australia.
  • Department of Civil and Environmental Engineering, Princeton University, Princeton, New Jersey 08544, United States.
  • Andlinger Center for Energy and the Environment, Princeton University, Princeton, New Jersey 08544, United States.
  • Princeton Materials Institute, Princeton University, Princeton, New Jersey 08544, United States.

ORCID-Profile: Nicholas J Caggiano, Madeleine S Armstrong, Aditya Rawal, Claire E White, Rodney D Priestley, Robert K Prud'homme

Förderung

  • Bill and Melinda Gates Foundation

Zitieren

APA

Caggiano, N. J., Armstrong, M. S., Georgiou, J. S., Rawal, A., Wilson, B. K., White, C. E., Priestley, R. D., & Prud'homme, R. K. (2023). Formulation and Scale-up of Delamanid Nanoparticles via Emulsification for Oral Tuberculosis Treatment. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00240

Vancouver

Caggiano NJ, Armstrong MS, Georgiou JS, Rawal A, Wilson BK, White CE, et al. Formulation and Scale-up of Delamanid Nanoparticles via Emulsification for Oral Tuberculosis Treatment. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00240

BibTeX
@article{Caggiano2023,
  author = {Caggiano, Nicholas J and Armstrong, Madeleine S and Georgiou, Joanna S and Rawal, Aditya and Wilson, Brian K and White, Claire E and Priestley, Rodney D and Prud'homme, Robert K},
  title = {Formulation and Scale-up of Delamanid Nanoparticles via Emulsification for Oral Tuberculosis Treatment},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00240}
}
Kostenlos starten →